Century Therapeutics (IPSC) Return on Capital Employed (2021 - 2026)

Century Therapeutics (IPSC) has 6 years of Return on Capital Employed data on file, last reported at 38.19% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 38.19%, down 6298.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 38.19% (down 6298.0% YoY), and the FY2025 annual result was 0.76%, up 1076.0% from the prior year.
• Return on Capital Employed declined to 38.19% in Q1 2026 per IPSC's latest filing, from 0.94% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 32.18% in Q3 2025 and troughed at 43.06% in Q1 2024.
• A 5-year average of 19.1% and a median of 28.52% in 2022 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2025 and 2026: Return on Capital Employed jumped 6996 bps in 2025, then sank 6298 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 28.52% in 2022, then sank by 42 bps to 40.56% in 2023, then surged by 73 bps to 10.85% in 2024, then soared by 91 bps to 0.94% in 2025, then slumped by 3945 bps to 38.19% in 2026.
• Business Quant data shows IPSC's Return on Capital Employed at 38.19% in Q1 2026, 0.94% in Q4 2025, and 32.18% in Q3 2025.